246 research outputs found

    Peritoneal Protein and Albumin Excretion as Markers of Cardiovascular Risk and Systemic Endothelial Dysfunction

    Get PDF
    BackgroundMicroalbuminuria is a marker of systemic endothelial dysfunction. We studied the relationship between peritoneal protein loss in peritoneal dialysis (PD) patients, which is conceptually analogous to microalbuminuria in non-uremic patients, and pre-existing vascular disease in new PD patients.MethodsPeritoneal total protein and albumin loss were quantified within 2 months of initiation of dialysis in 44 consecutive new PD patients, together with a standard peritoneal equilibration test. The results were compared according to the presence of cardiovascular disease (CVD) prior to initiation of dialysis, lean body mass, and serum albumin and C-reactive protein (CRP) concentrations.ResultsThe dialysate albumin concentration was closely correlated with the creatinine dialysate-to-plasma ratio at 4 hours (r = 0.601, p < 0.001). It was higher in patients with pre-existing CVD than in those without, when patients were analyzed according to diabetic status (one-way ANOVA, p = 0.004). In diabetic patients, the dialysate albumin concentration was significantly higher in patients with pre-existing CVD than in those without (0.754 ± 0.273 vs 1.088 ± 0.280 mg/μmol creatinine, p = 0.04). Multivariate analysis showed that only diabetic status and dialysate albumin concentration, but not peritoneal transport status or serum CRP, were independent predictors of pre-existing CVD. Although dialysate protein loss accounted for only 10.5 ± 4.4% of total protein catabolism, the dialysate protein level was significantly correlated with serum albumin concentration (r = −0.457, p = 0.002), percentage of lean body mass (r = −0.558, p < 0.001), and serum CRP concentration (r = 0.434, p = 0.003).ConclusionsPatients with CVD prior to initiation of dialysis have higher levels of dialysate albumin and total protein excretion, indicating that dialysate protein loss is a marker of underlying CVD. Dialysate protein and albumin excretion may provide a simple and convenient measure of vascular disease and endothelial dysfunction in PD patients

    Piperacillin/tazobactam Induced Myelosuppression

    Get PDF
    Neutropenia, secondary to immune destruction or maturation arrest, is the most commonly described adverse haematological effect of beta-lactam antibiotics. We describe a case of reversible pancytopenia, with evidence of hypocellular marrow, after a prolonged course of piperacillin/tazobactam for 26 days

    Definitive radiotherapy for early stage glottic cancer by 6 MV photons

    Get PDF
    Purpose: To evaluate the clinical outcome of early glottic cancer (GC) treated by primary radiotherapy (RT) with 6 MV photons. Methods and materials: We retrospectively reviewed the medical records of 695 consecutive patients with T1N0 and T2N0 GC treated between 1983 and 2005 by RT in our institution. Clinical outcome in terms of local control (LC), overall survival (OS) and cause- specific survival (CSS) rate were evaluated. Results: The median follow-up time was 10.5 years.The 10-year actuarial LC rates were as follows: T1A, 91%; T1B, 87%; T2, 77%. The 10-year OS were as follows: T1, 74.2%; T2, 70.7%. The 10-year CSS were as follows: T1, 97.7%; T2, 97.1%. Poorly differentiated histology and tumor biologically effective dose < 65 Gy.© 2012 Tong et al.; licensee BioMed Central Ltd.Link_to_subscribed_fulltex

    Waterproofed Photomultiplier Tube Assemblies for the Daya Bay Reactor Neutrino Experiment

    Full text link
    In the Daya Bay Reactor Neutrino Experiment 960 20-cm-diameter waterproof photomultiplier tubes are used to instrument three water pools as Cherenkov detectors for detecting cosmic-ray muons. Of these 960 photomultiplier tubes, 341 are recycled from the MACRO experiment. A systematic program was undertaken to refurbish them as waterproof assemblies. In the context of passing the water leakage check, a success rate better than 97% was achieved. Details of the design, fabrication, testing, operation, and performance of these waterproofed photomultiplier-tube assemblies are presented.Comment: 16 pages, 11 figures. Submitted to Nucl. Instr. Met

    Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer

    Get PDF
    AbstractStatins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR) inhibitors decreasing serum cholesterol and have shown promise in cancer prevention. In this study, we demonstrated the oncogenic role of HMGR in colorectal cancer (CRC) by disclosing increased HMGR activity in CRC patients and its enhancement of anti-apoptosis and stemness. Our previous studies showed that statins containing carboxylic acid chains possessed activity against histone deacetylases (HDACs), and strengthened their anti-HDAC activity through designing HMGR-HDAC dual inhibitors, JMF compounds. These compounds exerted anti-cancer effect in CRC cells as well as in AOM-DSS and ApcMin/+ CRC mouse models. JMF mostly regulated the genes related to apoptosis and inflammation through genome-wide ChIP-on-chip analysis, and Ingenuity Pathways Analysis (IPA) predicted their respective regulation by NR3C1 and NF-κB. Furthermore, JMF inhibited metastasis, angiogenesis and cancer stemness, and potentiated the effect of oxaliplatin in CRC mouse models. Dual HMGR-HDAC inhibitor could be a potential treatment for CRC

    The calling songs of some katydids (Orthoptera: Tettigonioidea) from the tropical forests of Southeast Asia

    Get PDF
    Katydids produce sound by stridulation of the tegmina for signalling and communication. Most katydids are known to sing at ultrasonic frequencies, as compared to crickets. This has drawn interest to investigate the biophysics of ultrasonic sound production and detection, evolution and ecology (including predator–prey interactions) of these katydids. However, most of these studies are based on species from the neotropics, whereas nearly nothing is known about the relatives from another hyper-diverse region, i.e., Southeast Asia. To address this, a concerted effort to document, record and describe the calling songs of Southeast Asian katydids, especially species which calls at ultrasonic frequencies, were conducted. A study spanning over two years (2018 to 2020) in Malay Peninsula (Singapore and Malaysia), Borneo (Brunei Darussalam and Sabah) and the Philippines revealed previously unknown calls of 24 katydid species from four subfamilies. The calling songs of Southeast Asian katydid species are highly diversified in both the time and frequency domains. Call structure can range from isolated syllables (e.g., Holochlora), continuous trills (e.g., Axylus philippinus) to short pulse-trains (e.g., Euanisous teuthroides) and complex echemes (e.g., Conocephalus spp.). 87.5 % of species have ultrasonic peak frequencies and 12.5 % can be considered extreme ultrasonic callers (peak frequency >40 kHz). The call spectrum ranges from tonal (e.g., spectral entropy = 6.8 in Casigneta sp. 2) to resonant (entropy = 8.8 in Conocephalus cognatus). Of the 24 species whose calls are described here, we also imaged and described the sound-producing structures of 18 species. This study provides a preliminary overview of the acoustic diversity of katydids in Southeast Asia and the authors hope to inspire further investigation into the bioacoustics of little-known katydids from Southeast Asia. Amassing a database of calling songs and sound-producing organs from different species can be important to address the taxonomy impediment while advancing our knowledge about the bioacoustics of Southeast Asian katydids

    ISPD Catheter-related Infection Recommendations: 2023 Update

    Get PDF
    Peritoneal dialysis (PD) catheter-related infections are important risk factors for catheter loss and peritonitis. The 2023 updated recommendations have revised and clarified definitions and classifications of exit site infection and tunnel infection. A new target for the overall exit site infection rate should be no more than 0.40 episodes per year at risk. The recommendation about topical antibiotic cream or ointment to catheter exit site has been downgraded. New recommendations include clarified suggestion of exit site dressing cover and updated antibiotic treatment duration with emphasis on early clinical monitoring to ascertain duration of therapy. In addition to catheter removal and reinsertion, other catheter interventions including external cuff removal or shaving, and exit site relocation are suggested

    The 5p15.33 Locus Is Associated with Risk of Lung Adenocarcinoma in Never-Smoking Females in Asia

    Get PDF
    Genome-wide association studies of lung cancer reported in populations of European background have identified three regions on chromosomes 5p15.33, 6p21.33, and 15q25 that have achieved genome-wide significance with p-values of 10−7 or lower. These studies have been performed primarily in cigarette smokers, raising the possibility that the observed associations could be related to tobacco use, lung carcinogenesis, or both. Since most women in Asia do not smoke, we conducted a genome-wide association study of lung adenocarcinoma in never-smoking females (584 cases, 585 controls) among Han Chinese in Taiwan and found that the most significant association was for rs2736100 on chromosome 5p15.33 (p = 1.30×10−11). This finding was independently replicated in seven studies from East Asia totaling 1,164 lung adenocarcinomas and 1,736 controls (p = 5.38×10−11). A pooled analysis achieved genome-wide significance for rs2736100. This SNP marker localizes to the CLPTM1L-TERT locus on chromosome 5p15.33 (p = 2.60×10−20, allelic risk = 1.54, 95% Confidence Interval (CI) 1.41–1.68). Risks for heterozygote and homozygote carriers of the minor allele were 1.62 (95% CI; 1.40–1.87), and 2.35 (95% CI: 1.95–2.83), respectively. In summary, our results show that genetic variation in the CLPTM1L-TERT locus of chromosome 5p15.33 is directly associated with the risk of lung cancer, most notably adenocarcinoma

    The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

    Get PDF
    Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
    corecore